Advertisement
Articles
Advertisement

Focus on Funding 12/1/06

Fri, 12/01/2006 - 10:08am


GOVERNMENT FUNDING

Argos Awarded NIH Contract for HIV Immunotherapy
Argos Therapeutics, Durham, N.C., announced that it has been awarded a $21 million National Institutes of Health (NIH) contract to develop novel HIV immunotherapy candidates. Argos is developing personalized, RNA-loaded dendritic cell immunotherapy products designed to train the patient’s immune system to recognize, target, and destroy unique features of their disease.
Full Article

India, ASEAN to Create Fund for Science
India and the Association of Southeast Asian Nations (ASEAN) have agreed to create a joint fund for the development of science and technology in the region. The agreement was reached at a two-day India-ASEAN technology summit.
Full Article

Korea to Invest $14 Billion in Biotech
Korea plans to invest $14.3 billion in biotechnology research and industrialization over the next 10 years to create a $60 billion market by 2016. The ministry’s "Bio-Vision 2016" plan puts priority on the acquisition of core technologies and the establishment of infrastructure that will help them in the applied industry, a ministry spokesman said.
Full Article

INDIVIDUAL/FOUNDATION FUNDING

Ludwig Fund Donates $120M for Cancer Research
A foundation created by American billionaire, Daniel K. Ludwig, will this year give six leading US institutions $20 million cash each, plus stock in a New York real estate holding company, to create Ludwig Centers that will each receive annual research funds of approximately $2 million in perpetuity. This is believed to be the largest single gift by a foundation for cancer research in the US.
Full Article

Institute for OneWorld Health Awarded $46M
The Institute for OneWorld Health, San Francisco, Calif., was awarded a grant of $46 million from the Bill & Melinda Gates Foundation to expand its unique research on new treatments to complement traditional approaches for fighting diarrhea.
Full Article

PRIVATE FUNDING

Solstice Neurosciences Raises $85M in Private Financing
Solstice Neurosciences Inc., Malvern, Pa., a privately held biopharmaceutical company, has received a combined $85 million in Series B Equity funding and Debt financing to support the company's ongoing initiatives related to movement disorders and treatment for cervical dystonia.
Full Article

Cerenis Therapeutics Closes $53.5M in Financing
Cerenis Therapeutics SA, Ann Arbor, Mich., focused on the discovery, development, and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases, closed a $53.5 million equity financing round, to support its clinical development programs.
Full Article

Neurotech Completes $35M Private Equity Financing
Neurotech Pharmaceuticals Inc., Lincoln, R.I., raised $35 million in a Series B private equity financing that will allow it to continue three important phase II studies that the company is carrying out in atrophic macular degeneration and early- and late-stage retinitis pigmentosa.
Full Article

VaxInnate Secures $40M in Series C Financing
VaxInnate Corp., Cranbury, N.J., has secured $40 million in Series C financing to continue developing novel, proprietary vaccines for both pandemic and seasonal influenza based on its Toll-like receptor technology platform.
Full Article

Cytheris Closes on $ 30.7M in Series B Financing
ABN AMRO Capital Life Sciences announced a EUR4 million investment in Cytheris, Paris, France, a privately held biopharmaceutical company focused on immuno-modulation. The investment is part of a EUR24.3 million (US$30.7 million approx.) Series B financing to allow Cytheris to complete phase II trials of its IL-7 program for HIV.
Full Article

NovImmune Raises CHF 58M in Series B Funding
NovImmune SA, Geneva, Switzerland, which focuses on immune mechanisms to clinically impact immune-related diseases, inflammation, and organ transplantation, has closed a CHF 58 million (US$46 million, EUR 37 million) Series B private financing round to advance further products from its pipeline of fully human proprietary antibodies into clinical development.
Full Article

GRANTS AVAILABLE

Pilot and Feasibility Program Related to the Kidney
Agency: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This invites applications to foster the development of high-risk pilot and feasibility research by newly independent or established investigators, to develop new ideas sufficiently to allow for subsequent submission of R01 applications focusing on research problems relevant to the study of both acute and chronic kidney diseases, and their complications, in both the adult and pediatric populations.
Full Article

NIH Exploratory/Developmental Research Grant Program
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant application solicits exploratory and developmental research projects by providing support for the early and conceptual stages of these projects, which may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
Full Article

Venous Thrombosis and Thromboembolism in the Elderly
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Jan 10, 2007
Description: This grant supports research to explore the epidemiology, pathophysiology, and clinical aspects of venous thrombosis (VT) and thromboembolism in the elderly.
Full Article

Development of Disease Biomarkers
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This funding opportunity will provide resources to validate candidate biomarkers for well-defined human diseases of liver, kidney, urological tract, digestive and hematologic systems, and endocrine and metabolic disorders, diabetes and its complications, and obesity.
Full Article

Innovative and Exploratory Research in Digestive Diseases and Nutrition
Agency: National Institutes of Health
Estimated Funding: $200,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant invites applications from investigators with research interests in gastroenterology, hepatology, obesity, and nutrition to stimulate the application of highly novel approaches to important areas of digestive diseases (including associated cancers) and nutrition research.
Full Article

Drug Discovery for Nervous System Disorders
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This funding opportunity announcement seeks grant applications from applicant organizations directed toward the discovery, development, and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders.
Full Article

Animal Models of NIDDK-Relevant Diseases
Agency: National Institutes of Health
Estimated Funding: $250,000
Due Date for Applications: Multiple dates, see Web site
Description: This grant is to support the development and validation of new animal models of NIDDK-relevant diseases to facilitate preclinical testing of diagnostic, preventive, or or therapeutic interventions.
Full Article

Symptom Clusters in Cancer and Immune Disorders
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This announcement invites applications to: identify and assess biobehavioral characteristics of symptom clusters, or to design and test interventions that lead to clear outcomes.
Full Article

Insulin Signaling and Receptor Cross-Talk
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute on Aging (NIA) invite investigator-initiated research grant applications to investigate crosstalk in insulin responses at molecular, cellular, and physiological levels.
Full Article

Research Grants for Studies of Hepatitis C in the Setting of Renal Disease
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This seeks experienced and new investigators to submit research grant applications to pursue basic and clinical investigations in order to better understand the pathogenesis, natural history, therapy and prevention of hepatitis C in the setting of renal disease or renal transplantation.
Full Article

Health Disparities in NIDDK Diseases
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant solicits applications for research to understand and mitigate issues of health disparities in high priority diseases within its scope, including diabetes, obesity, nutrition-related disorders, hepatitis C, gallbladder disease, H. Pylori infection, sickle cell disease, kidney diseases, and metabolic, gastrointestinal, hepatic, and renal complications from infection with HIV.
Full Article

Mechanisms of Alcohol-Associated Cancers
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant invites applications that will employ an integrative approach using state-of-the-art technologies to gain insight into the molecular and biochemical mechanisms by which chronic alcohol consumption leads to the development of cancers of various organs such as oral cavity, pharynx, larynx, esophagus, stomach, large intestine, liver, and breast.
Full Article

Erythroid Lineage Molecular Toolbox
Agency: National Institutes of Health
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: The aim of this program is to contribute to a complete description of expressed erythroid molecular biological components and to create reagents useful for study of the erythroid cell lineages.
Full Article

Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis
Agency: National Cancer Institute
Estimated Funding: N/A
Due Date for Applications: Multiple dates, see Web site
Description: This grant seeks clinicians, epidemiologists, geneticists, statisticians, and translational researchers working in the field of cancer control and prevention to improve existing models for cancer risk and prognosis by developing innovative research projects that use existing data, develop new models for risk and prognosis, and validate new models.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading